- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01997879
Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers
August 18, 2023 updated by: Aerie Pharmaceuticals
An Open-label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution, 0.02% in Healthy Volunteers
The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85283
- Celerion
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy adult male or female subjects at least 18 years of age.
- Within 25% of their ideal weights.
- Medically healthy subjects with clinically insignificant screening results (laboratory profiles, medical histories, ECGs, physical exam) as determined by the Investigator.
- Non-tobacco/nicotine using subjects (minimum of 3 months non-tobacco/nicotine use prior to first dose).
- Subjects with two normal (non-diseased) eyes, defined as nonclinically significant in the opinion of the investigator.
- Intraocular pressure between 14 and 20 mm Hg (inclusive) in each eye at Screening/Qualification.
- Best-corrected visual acuity (BCVA) in each eye of 20/40 or better.
- Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements.
Exclusion Criteria:
- Chronic or acute ophthalmic disease including glaucoma, macular degeneration, clinically significant cataract (primary or secondary). Previous cataract surgery.
- Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
- Previous glaucoma intraocular surgery or glaucoma laser procedures.
- Refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
- Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months (e.g., laser treatment for glaucoma or retina).
- Evidence of ocular infection, inflammation, cystoid macular edema, clinically significant blepharitis or conjunctivitis at (Screening/ Qualification), or a history of herpes simplex keratitis.
- Ocular medication of any kind within 30 days of Screening/ Qualification
- Any abnormality preventing reliable applanation tonometry of either eye.
- Central corneal thickness greater than 600 µm.
- Cannot demonstrate proper delivery of the eye drop.
- Blood donations or blood loss, within the past 3 months, that would put the patient at risk with the multiple blood samples required in the present study.
- Clinically significant abnormalities in laboratory tests at screening.
- Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
- Participation in any investigational study within the past 30 days prior to screening.
- Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
- Due to status of preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a physician-supervised form of birth control for at least the last two months. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine or serum pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AR-13324 Ophthalmic Solution, 0.02%
Eyedrop
|
Eyedrop
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Assessment
Time Frame: 8 Days
|
Blood samples obtained to evaluate the systemic exposure (Area Under the Curve (AUC), Maximum Concentration, Time and half-life (Cmax, tmax and t ½)) to ocularly instilled AR-13324 and its metabolites as appropriate.
|
8 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
November 19, 2013
First Submitted That Met QC Criteria
November 25, 2013
First Posted (Estimated)
November 28, 2013
Study Record Updates
Last Update Posted (Actual)
August 22, 2023
Last Update Submitted That Met QC Criteria
August 18, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR13324-CS101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on AR-13324 Ophthalmic Solution, 0.02%
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedPrimary Open Angle Glaucoma or Ocular HypertensionUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedHealthy SubjectsUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle GlaucomaUnited States